NCT06493604View on ClinicalTrials.gov

A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

February 27, 2025

Study Completion Date

February 27, 2025

Conditions
Dry Eye Disease
Interventions
DRUG

Reproxalap Ophthalmic Solution (0.25%)

Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days

DRUG

Vehicle Ophthalmic Solution

Vehicle Ophthalmic Solution administered six times over two consecutive days

Trial Locations (1)

01810

Andover Eye Associates, Andover

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY

NCT06493604 - A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease | Biotech Hunter | Biotech Hunter